Insurer: No more prior auths for opioid addiction meds October 27, 2016 By Tracey Walker As part of efforts to combat the opioid epidemic, Cigna removes prior authorization from medication-assisted treatment for opioid use disorder. Online drug pricing tools that influence consumers October 25, 2016 By Mari Edlin Consumers are demanding transparency in the prices of drugs. Here’s how they are getting it. Copay assistance programs: Managed care pros and cons Do copay assistance program offer a long-term solution for patients? Experts weigh in. Are oncology pathways effective? AMCP presenters weigh in October 06, 2016 By Aubrey Westgate Faced with a proliferation of oncology treatments, payers have started using oncology pathways. But what do these programs look like, and are they really working? Study: Use of short-acting opioids decrease, long-acting opioids increase October 06, 2016 By Tracey Walker Executives need to increase awareness in the category and ensure prescribers are aware of CDC guidelines for opioid prescribing and the prescription drug monitoring programs. Biosimilars and interchangeable biologics: News to watch October 05, 2016 By Aubrey Westgate Biosimilars in the United States are slowly gaining traction, but widespread confusion and legal barriers remain. Drug pipeline developments: Alopecia areata and atopic dermatitis Promising treatments are coming for alopecia areata and atopic dermatitis, but they will come at a high cost. Nearly half of BCBS members discontinue this RA drug after 1 year October 05, 2016 By Tracey Walker Analysis from Prime shows that improvements in persistency, adherence is key in RA treatments. Health execs must brace for autoimmune drug changes October 04, 2016 By Tracey Walker A comprehensive understanding of this rapidly increasing drug class is essential to integrate pharmacy and medical claim information. Five specialty pharmaceutical trends to watch October 04, 2016 By Aubrey Westgate Approvals of specialty pharmaceuticals have far outpaced traditional drugs, and that trend will continue. But that’s not the only specialty medication trend that healthcare executives should have on their radar.